Building an OXPHOS-Deficient Cell Line

Three routes, three kinds of deficiency.

The Three Routes

RouteWhat is removedTimeReversibility
ρ0 (mtDNA depletion)All mtDNA-encoded subunits4–12 weeksEffectively irreversible
Nuclear gene knockout (e.g. NDUFS1, SDHB)One complex6–16 weeksClonal; irreversible
CybridmtDNA variant, common nuclear background8–16 weeksIrreversible

Important distinction. ρ0 cells remove complex I, III, IV and ATP synthase subunits simultaneously while leaving complex II intact. A nuclear knockout removes one complex. The two are not interchangeable models, and a phenotype in ρ0 cells cannot be attributed to a specific complex.

Part 1 — Generating ρ0 Cells

StepDetailNote
AgentLow-dose ethidium bromide, or ddCEthidium bromide intercalates mtDNA preferentially at low dose
SupplementationUridine (50 µg/mL) and pyruvate (1 mM)Required for growth once mtDNA is lost
Duration4–12 weeks, with periodic testingLonger for some lines
VerificationmtDNA qPCR; OCR; complex IV activityMultiple independent checks
MaintenanceContinued uridine and pyruvateRemoval causes death
DocumentationPassage and generation timeAdaptation accumulates

Caveat on the auxotrophy. Uridine is required because dihydroorotate dehydrogenase, a step in pyrimidine synthesis, is mitochondrial and depends on the electron transport chain. Pyruvate provides a cytosolic NAD⁺ regeneration route. Both must be present from the point of mtDNA loss, and their presence is part of the model's definition, not a technical detail.

Part 2 — What Adapts

AdaptationConsequence
Increased glycolytic capacityLactate production rises; glucose dependence increases
Altered mitochondrial massContent may rise or fall depending on the line
Changes in aspartate supplyProliferation may require exogenous aspartate or pyruvate
Altered signallingAMPK activation, HIF stabilisation in some lines
SelectionClones with the fastest growth dominate

Important distinction. A ρ0 line is a long-term adaptation, not an acute knockout. Many of its phenotypes reflect what the cell did over weeks to survive, and comparisons with the parental line confound the loss of mtDNA with that adaptation. An inducible system, where available, is the cleaner design for acute questions.

Part 3 — Nuclear Knockouts

TargetEffectCaveat
NDUFS1, NDUFA9Complex I lossSome lines cannot tolerate it
SDHB, SDHCComplex II lossSuccinate accumulates; epigenetic effects
UQCRBComplex III lossLethal in many lines
COX10, SCO2Complex IV assemblyPartial loss often obtainable
ATP5A1ATP synthaseViable in some lines; gradient hyperpolarises

Readout note. A nuclear knockout must be verified at three levels: genotype, protein (subunit immunoblot), and function (substrate-specific respiration). A genotype-only verification can miss a hypomorphic allele, and in the ETC a partial loss often produces a different phenotype from a complete one.

Part 4 — Verification Package

CheckMethodPassing criterion
mtDNA contentqPCR, mitochondrial versus nuclear ampliconUndetectable or strongly reduced for ρ0
Complex activityBlue-native in-gel activity; isolated enzyme assayAbsent for the targeted complex
Substrate-specific respirationPermeabilised cellsAbsent response to the relevant substrate
Complex II controlSuccinate-linked respirationPreserved in ρ0
Growth requirementUridine/pyruvate dependenceRequired for ρ0
ContentCitrate synthase activity or mtDNAReported alongside function

The sixth row matters for interpretation: citrate synthase activity is a standard content marker, and a line with reduced content but normal per-mitochondrion respiration is a different model from one with a specific complex defect.

Part 5 — Common Failures

  • • ρ0 described as "OXPHOS-deficient" without noting the auxotrophy and adaptation.
  • • Single verification method used, usually mtDNA qPCR alone.
  • • Uridine or pyruvate omitted, so the line cannot grow and the experiment is abandoned.
  • • Complex II control omitted, so a global assay problem looks like a specific defect.
  • • Nuclear knockout verified by genotype only.
  • • Parental comparison at a different passage, confounding adaptation with genotype.
  • • Content not measured, so a specific defect is indistinguishable from fewer mitochondria.
  • • Cybrid nuclear background not matched, confounding the mtDNA variant with nuclear variation.

Part 6 — Where This Article Connects

This is the model-building article of the mitochondrial cluster. The respiratory chain article covers what the complexes are and which readouts distinguish capacity, coupling and content; the Seahorse article covers the functional measurement; and the inhibitor article covers acute alternatives to genetic models.

If you need OXPHOS-deficient models with a three-level verification package, we can scope the build with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

ρ0 generation efficiency, adaptation and viability vary widely between lines, and nuclear knockouts of ETC subunits are not tolerated in all backgrounds.

Loss of mtDNA is not equivalent to loss of a specific complex, and a verified defect does not establish that respiratory capacity limits a phenotype.

Scientific interpretation and experimental design

  • • Three routes, three models. Choose by question.
  • • ρ0 is auxotrophic. Uridine and pyruvate are part of the model.
  • • Adaptation is the confound. Match passage, or use inducible systems.
  • • Verify at three levels. Genotype, protein, function.
  • • Keep complex II as the control.
  • • Measure content. Fewer mitochondria is not a specific defect.

Selected references for further reading

  • • King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246:500–503.
  • • Chandel NS, Schumacker PT. Cells depleted of mitochondrial DNA (ρ0) yield insight into physiological mechanisms. FEBS Letters. 1999;454:173–176.
  • • Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nature Reviews Molecular Cell Biology. 2022;23:141–161.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: